Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma

Autophagy. 2023 Apr;19(4):1184-1198. doi: 10.1080/15548627.2022.2117893. Epub 2022 Sep 7.

Abstract

cld-CASP3: cleaved caspase 3; cld-PARP: cleaved PARP; DTP: drug tolerant persister; GO: Gene Ontology; GTEx: The Genotype-Tissue Expression; HCC: hepatocellular carcinoma; HCQ: hydroxychloroquine; IC50: half maximal inhibitory concentration value; KEGG: Kyoto Encyclopedia of Genes and Genomes; LAPTM5: lysosomal protein transmembrane 5; NT: non-targeting; PDC: patient-derived primary cell lines; PDO: patient-derived primary organoid; TCGA: The Cancer Genome Atlas.

Keywords: Autophagy; LAPTM5; drug resistance; lenvatinib; liver cancer; whole-genome CRISPR-Cas9 screen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autophagy
  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / genetics
  • Carcinoma, Hepatocellular* / pathology
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • Humans
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / genetics
  • Liver Neoplasms* / pathology
  • Membrane Proteins / genetics
  • Poly(ADP-ribose) Polymerase Inhibitors

Substances

  • lenvatinib
  • Poly(ADP-ribose) Polymerase Inhibitors
  • LAPTM5 protein, human
  • Membrane Proteins

Grants and funding

This work was supported by the National Natural Science Foundation of China (No. 81961128025), Research Projects from the Science and Technology Commission of Shanghai Municipality (grants 19XD1420700, 21JC1401200, 21JC1410100), Shanghai Municipal Key Clinical Specialty and the Beijing iGandan Foundation (GDXZ-08-17).